ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1619

Immunoglobulin G Subclass Ordering Patterns for IgG4-Related Disease at an Academic Medical Center

Lena Eder1 and David Leverenz2, 1Duke University Hospital, Chapel Hill, NC, 2Duke University, DURHAM, NC

Meeting: ACR Convergence 2020

Keywords: Decision analysis, Diagnostic criteria, education, medical, IgG4 Related Disease, Qualitative Research

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 9, 2020

Title: Measures & Measurement of Healthcare Quality Poster

Session Type: Poster Session D

Session Time: 9:00AM-11:00AM

Background/Purpose: We have noticed an increasing number of serum IgG4 levels ordered over the last several years at our institution. This study was performed to better understand the clinical indications for IgG4 testing among inpatient general medicine providers and how those trends have changed from 2015 to 2019.  We also sought to determine if there was any comparative change in rheumatology providers’ behavior regarding IgG4 testing.

Methods: We used SlicerDicer, an analytic tool in our EHR, to identify patients with IgG subclasses ordered by inpatient general medicine or rheumatology providers in 2015 and 2019. Charts were manually reviewed to determine clinical indications for IgG subclass testing as determined by provider documentation at the time of ordering. Using a pre-specified adjudication algorithm, patients were excluded if IgG subsets were sent for an indication other than IgG4-Related Disease (IgG-RD) or if they already had a known diagnosis of IgG4-RD. For included patients, we also evaluated IgG4 levels, imaging, biopsies, and final diagnoses. Fisher’s exact test (Social Science Statistics open software) was used to compare 2015 and 2019 data. Other data were analyzed using descriptive statistics.

Results: Among general medicine providers, there was a significant increase in patients tested for suspected IgG4-RD with serum IgG subclasses from 2015 (n = 31, 0.12% of all patients with any lab order) to 2019 (n = 77, 0.26%), p< 0.001 (table 1). There were no changes in the proportion of patients with elevated IgG4 levels, biopsies obtained, or a diagnosis of IgG4-RD from 2015 to 2019 (table 2). Notably, only 1 general medicine patient was diagnosed with IgG4-RD in 2015 and 1 in 2019. There was a significant decrease in the proportion of general medicine patients tested with IgG subclasses for IgG4-RD due to retroperitoneal fibrosis (10% in 2015 vs 0% in 2019, p=0.022) and a trend towards more patients tested due to hepatobiliary disease (13% vs 30%, p=0.0861) and orbital inflammatory disease (0% vs 9%, p=0.0571), table 3. There were no significant changes in IgG subclass testing patterns by rheumatology providersfrom 2015 to 2019.

Conclusion: Despite a more than two-fold increase in IgG subclass testing for IgG4-RD by inpatient general medicine providers from 2015 to 2019, the number of patients ultimately diagnosed with IgG4-RD did not change. The trend towards increased IgG subclass testing for hepatobiliary disease and orbital inflammatory disease suggests increased provider awareness of some of this condition’s protean manifestations beyond the pancreas; however, the decrease in IgG subclass testing for retroperitoneal fibrosis and the minimal testing for other major clinical manifestations of IgG4-RD in either 2015 or 2019 suggests that this condition remains under-recognized. In contrast, there were no major changes in IgG subclass testing by rheumatologists from 2015 to 2019. Overall, this study reveals potential knowledge gaps regarding the workup of IgG4-RD among inpatient internal medicine providers and highlights the need for an educational intervention to address appropriate indications for IgG subclass testing in different clinical scenarios.

Table 3. A review of clinical characteristics and indications of patients tested for IgG4-RD.


Disclosure: L. Eder, None; D. Leverenz, None.

To cite this abstract in AMA style:

Eder L, Leverenz D. Immunoglobulin G Subclass Ordering Patterns for IgG4-Related Disease at an Academic Medical Center [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/immunoglobulin-g-subclass-ordering-patterns-for-igg4-related-disease-at-an-academic-medical-center/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/immunoglobulin-g-subclass-ordering-patterns-for-igg4-related-disease-at-an-academic-medical-center/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology